Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 6.82% | |
| Bollinger Band Squeeze | Range Contraction | 6.82% | |
| Bollinger Band Squeeze | Range Contraction | 8.80% | |
| NR7 | Range Contraction | 8.80% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 14 hours ago |
| Up 10% | about 14 hours ago |
| Up 1 ATR | about 14 hours ago |
| 20 DMA Support | about 14 hours ago |
| Rose Above Previous Day's High | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.75 |
| 52 Week Low | 1.4 |
| Average Volume | 152,037 |
| 200-Day Moving Average | 3.53 |
| 50-Day Moving Average | 2.65 |
| 20-Day Moving Average | 2.21 |
| 10-Day Moving Average | 2.25 |
| Average True Range | 0.24 |
| RSI (14) | 48.45 |
| ADX | 27.49 |
| +DI | 16.56 |
| -DI | 19.97 |
| Chandelier Exit (Long, 3 ATRs) | 2.02 |
| Chandelier Exit (Short, 3 ATRs) | 2.65 |
| Upper Bollinger Bands | 2.36 |
| Lower Bollinger Band | 2.05 |
| Percent B (%b) | 0.96 |
| BandWidth | 14.03 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.16 |
| MACD Histogram | 0.0381 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.70 | ||||
| Resistance 3 (R3) | 2.69 | 2.56 | 2.64 | ||
| Resistance 2 (R2) | 2.56 | 2.48 | 2.57 | 2.62 | |
| Resistance 1 (R1) | 2.46 | 2.42 | 2.51 | 2.47 | 2.60 |
| Pivot Point | 2.33 | 2.33 | 2.36 | 2.34 | 2.33 |
| Support 1 (S1) | 2.23 | 2.25 | 2.28 | 2.24 | 2.10 |
| Support 2 (S2) | 2.10 | 2.19 | 2.11 | 2.08 | |
| Support 3 (S3) | 2.00 | 2.10 | 2.06 | ||
| Support 4 (S4) | 2.01 |
